Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Appointed director
|
|
Oxford Immunotec Global PLC (OXFD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/08/2021 |
GN
| Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea |
| 02/04/2021 |
GN
| Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses |
| 01/21/2021 |
GN
| MERGER INVESTIGATION: Halper Sadeh LLP Investigates CMD, COHR, PS, OXFD; Shareholders Are Encouraged to Contact the Firm |
| 01/20/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Oxford Immunotec Global PLC Buyout |
| 01/13/2021 |
GN
| Oxford Immunotec's T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva's VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study |
| 12/16/2020 |
GN
| Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week |
| 12/10/2020 |
GN
| Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea |
| 12/02/2020 |
GN
| Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan |
| 11/23/2020 |
GN
| Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020 |
| 11/10/2020 |
GN
| Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec's T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec |
| 11/05/2020 |
GN
| Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent Kit |
| 11/03/2020 |
GN
| Oxford Immunotec Reports Third Quarter 2020 Financial Results |
| 10/22/2020 |
GN
| UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials |
| 10/21/2020 |
GN
| Oxford Immunotec Schedules Third Quarter 2020 Earnings Release and Conference Call for November 3, 2020 |
| 09/29/2020 |
GN
| Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of Two |
| 09/22/2020 |
GN
| Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test |
| 08/04/2020 |
GN
| Oxford Immunotec Reports Second Quarter 2020 Financial Results |
| 07/21/2020 |
GN
| Oxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020 |
| 07/20/2020 |
GN
| Oxford Immunotec Announces Agreement with Stop TB Partnership - Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden Countries |
| 04/29/2020 |
GN
| Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020 |
| 04/21/2020 |
GN
| Oxford Immunotec announces successful re-registration of the T-SPOT®.TB test in China |
| 02/24/2020 |
GN
| Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020 |
| 02/20/2020 |
GN
| Oxford Immunotec Announces New Data on the Utility of T-SPOT®.CMV in Kidney and Stem Cell Transplant |
| 01/06/2020 |
GN
| Oxford Immunotec to Present at the 38th Annual J.P. Morgan Healthcare Conference |
| 11/25/2019 |
GN
| Oxford Immunotec to Participate in Two Investor Conferences |
| 11/05/2019 |
GN
| Oxford Immunotec Reports Third Quarter 2019 Financial Results |
| 08/21/2019 |
GN
| Oxford Immunotec to Participate in Two Upcoming Investor Conferences |
| 07/18/2019 |
GN
| Oxford Immunotec Schedules Second Quarter 2019 Earnings Release and Conference Call for August 6, 2019 |
| 06/24/2019 |
GN
| Oxford Immunotec Appoints Patrick J. Balthrop, Sr. as Chairman |
| 05/17/2019 |
GN
| Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel |
| 05/14/2019 |
GN
| Oxford Immunotec to Present at the UBS Global Healthcare Conference |
| 03/28/2019 |
GN
| Oxford Immunotec Announces New Initiative to Bring the Benefit of Modern Tuberculosis Testing to the Russian Federation |
| 02/19/2019 |
GN
| Oxford Immunotec Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 11, 2019 |
| 01/06/2019 |
GN
| Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018 |
|
|
|